Compare VYNE & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYNE | ALLR |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | United States |
| Employees | 10 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3M | 19.3M |
| IPO Year | 2017 | 2021 |
| Metric | VYNE | ALLR |
|---|---|---|
| Price | $0.68 | $1.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | ★ 232.7K | 201.5K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $320,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.77 |
| 52 Week High | $1.96 | $2.35 |
| Indicator | VYNE | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 66.11 | 50.42 |
| Support Level | $0.56 | $1.01 |
| Resistance Level | $0.69 | $1.45 |
| Average True Range (ATR) | 0.02 | 0.13 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 88.82 | 31.25 |
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.